Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06620627 · ClinicalTrials.gov registry record

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection

A clinical trial of Colorectal Cancer Screening, sponsored by Natera.

Recruiting
Registry status
5,000
Enrollment target
1
Study location

NCT06620627 is a study of Colorectal Cancer Screening that is actively recruiting participants, run by Natera. The registered enrollment target is 5,000 participants, below the 5,620-participant average among 19 other Colorectal Cancer Screening trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06620627, a study of Colorectal Cancer Screening, is actively recruiting participants, sponsored by Natera.

RECRUITING
Registry status
5,000 participants
Enrollment target
1
Study location

Study Summary

The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

Study Locations (1)

Texas

  • Natera - Austin

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2024-01-26
Est. Completion 2025-10-31

Sponsor

Natera

27 total trials

What the Registry Record Tells You About NCT06620627

The ClinicalTrials.gov registry entry for NCT06620627 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,620-participant average among 19 other Colorectal Cancer Screening trials with a reported enrollment target (11% lower). The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer Screening appearing as the primary indexed condition, and to 0 interventions.

NCT06620627 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06620627 about?

NCT06620627 is a clinical study titled "Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection". The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.

What is the current status of trial NCT06620627?

This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2024-01-26. Estimated completion is 2025-10-31.

What conditions does trial NCT06620627 study?

This clinical trial studies the following conditions: Colorectal Cancer Screening.

Who is sponsoring clinical trial NCT06620627?

This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06620627 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer Screening

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.